Clinical Trials Directory

Trials / Terminated

TerminatedNCT04595851

Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications

Implementation of a Model Integrating Primary and Oncology Care for Patients Taking Oral Anticancer Agents (OAA)

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
6 (actual)
Sponsor
University of Michigan Rogel Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care coordination between pharmacists working in oncology practices and those working in primary care practices (Pharmacists Coordinated care Oncology Model \[PCOM\]). This is a pilot study in which the investigators will examine the association between outcome measures, but the study design and sample size are insufficient to quantify the impact of OAA initiation or OAA adherence on adherence to chronic medications. This pilot study and data analyses are being done in preparation for a larger, controlled study.

Conditions

Interventions

TypeNameDescription
OTHERPatient Reported Outcome Measure (PROM)Participants will complete a PROM (Michigan Oncology Quality Consortium, Patient Assessment Tool for Oral Chemotherapy) for their oral anticancer agent (OAA) at two timepoints over 2 months, to assess patient symptoms and adherence to OAA.
OTHERComprehensive Medication Review (CMR)Following the first PROM, participants will be contacted by the primary care pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. If warranted, a follow-up CMR will take place after the second PROM.
OTHERCommunications between oncology and primary care pharmacistsThroughout the study, the oncology and primary care pharmacists will communicate about medications through the electronic medical record.

Timeline

Start date
2021-03-26
Primary completion
2022-07-14
Completion
2022-07-14
First posted
2020-10-22
Last updated
2022-11-22

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04595851. Inclusion in this directory is not an endorsement.